论文部分内容阅读
据最近出版的《科学》杂志报道,美国研究人员已鉴定出一种可对胆固醇肠内吸收产生重要作用的蛋白质。该研究发现可指导今后进行新的降血脂治疗。来自于美国新泽西州Kenilworth市Schering-Plough研究所的Scott W Altmann博士及其同事应用基因组学-生物信息学方法对胆固醇吸收过程中所涉及的主要基因进行探寻,随后鉴定出一种可靠的候选基因NPCI LI(Niemann-Pick C1 like 1)。为进一步揭示NPC1L1基因,研究人员在将一种对胆固醇肠吸收产生关键作用的蛋白进行编码后,发现NPC1L1基因在小肠内的表达有所增加。实验表明缺乏NPC1L1基因的小鼠的胆固醇吸收可减少70％左右,且胆汁酸的补充不会影响此过程。该研究结果提示NPC1L1基因可能是最近批准的降脂药物依
According to a recent issue of Science, U.S. researchers have identified a protein that plays an important role in the intestinal absorption of cholesterol. The study found that can guide the future of new lipid-lowering treatment. Scott W Altmann, Ph.D., from Schering-Plow Institute, Kenilworth, NJ, USA, and colleagues used genomics-bioinformatics to explore the major genes involved in cholesterol absorption and subsequently identified a reliable candidate gene NPCI LI (Niemann-Pick C1 like 1). To further reveal the NPC1L1 gene, researchers found that an expression of the NPC1L1 gene in the small intestine was increased after encoding a protein that plays a key role in intestinal absorption of cholesterol. Experiments show that the lack of NPC1L1 gene in mice cholesterol absorption can be reduced by about 70%, and bile acid supplement does not affect the process. The findings suggest that the NPC1L1 gene may be the recently approved lipid-lowering drug